Alira Health’s COVID-19 Response

News
Published on:
April 4, 2020

Throughout the COVID-19 pandemic, the Alira Health team has worked closely with our partners throughout the healthcare ecosystem to help support the community and get resources into the hands of those that need it most. Our work includes:

Mary McNamara-Cullinane

Just-in-time regulatory support

Our regulatory team, led by Mary McNamara-Cullinane, has been working closely with our clients and FDA on several fronts, including:

  • One Emergency Use Authorization to wean patients off ventilators is pending at FDA
  • Two ventilator accessory Emergency Use Authorizations
  • One remote patient monitoring system Emergency Use Authorization
  • Additional Emergency Use Authorizations for disinfectants and sanitizers are currently pendin

In addition, Mary is on two national task forces providing regulatory guidance for respirator and mask manufacturers.

Led by David Uffer, Senior Partner and VP of MedTech and Deepak Sahu, Partner, the Alira Health team has worked closely with partners across the healthcare ecosystem to provide:

David Uffer

Support across the supply chain

  • Supply chain reinforcement by connecting hospitals, suppliers, and governments to critical resources, including PPE and ventilators.
  • Support in establishing a PPE factory in India by connecting funding and technology with regional officials. This factory has been scaling up to produce more than 100,000 pairs of gloves and gowns.
  • Collaboration with the CEO of a Massachusetts hospital to connect the hospital’s innovation center with manufacturing partners for PPE technologies.
Deepak Sahu

Analysis and operational assistance

  • Introductions of an N95 respirator technology to potential manufacturers and investors.
  • Partnership with experienced industry professionals (who developed HIV screening protocols) to develop COVID-19 screening protocols. Looking past the current crisis, the team is also looking at how screening should be considered long-term.
  • Helping a low-cost ventilator company to scale up. The company is connected with several Massachusetts universities and has seen positive clinical results.

If you need help with your own COVID-19 relief work, please contact us to discuss how we can help support your efforts.

Related news

Multimedia September 29, 2022
Regulatory Strategy for Registering Rare Disease Products in the EU
In this webinar we will focus on how to benefit, today and in the future, from the orphan drug program and build a regulatory strategy for successful rare disease product registration(...)
Drug Development Rare Disease Regulatory
Events September 7, 2022
MDIC Annual Patient Forum 2022
We are pleased to share that we will be joining as speakers MDIC Annual Patient Forum 2022 – a key platform for the discussion of how to transform patient engagement throughout the(...)
Clinical Trials MedTech Patient Engagement
Events August 31, 2022
BIOMEDevice 2022
We are excited to share that we will be joining BIOMEDevice 2022 as speakers! This event will bring engineers, business leaders, disruptive companies, and innovative thinkers from the(...)
Investor Relations Medical Devices MedTech
Multimedia August 29, 2022
Webinar Replay: Clinical Trial Management in MedTech & Working with CROs
As a MedTech company, understanding clinical trial management is critical, and working with CROs is part of the journey. Join the webinar to learn about this crucial topic.
Clinical Trial Management CRO MedTech
Events August 23, 2022
MedtechVision 2022
Join us at the MedtechWomen MedtechVision Conference, where we will be presenting a state of the Medtech Industry Report with an overview of the innovation and advancement and much more.
Diagnotics MedTech Patient Centricity
Publications August 4, 2022
White Paper: New European Health Technology Assessment Regulation
In this white paper, we provide an overview of this new regulation, including key points of the new European Health Technology Assessment Regulation, its methodology, and its timelines.
MedTech Regulatory
Publications July 15, 2022
How to leverage registry-based studies to generate high-quality Real-World Evidence
The use of Real-World Evidence (RWE) in regulatory decision making will support the development and application of better medicines.
Real-World Evidence Registry-based studies Regulatory RWE
Welcome to Alira Health. This site is best viewed in Chrome, Microsoft Edge, or Firefox.